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Within thethreedecades sincethe beginnings ofthefieldofclinical renal transplantation there
have been four phases in blood transfusion policies, swinging from liberal transfusions to
avoidance of transfusions, followed by a repeat cycle of deliberate transfusions and at present
turning back to abstinence again. Because ofimproving skills at the prevention and treatment of
rejections, the beneficial effects ofrandom transfusions in the transplant population as a whole is
marginal. Thiscomes atatimewhencommunity fearsofblood-borneinfections and the prospects
ofsupporting redcellproductionbytheuseofEPOhaveemerged asnewfactors in bloodbanking.
Observations on patients at risk for graft loss, namely those having rejection episodes, indicate
that a beneficial blood transfusion effect still exists, however. Future application of deliberate
HLA antigen exposure in conjunction with novel immunological manipulations may provide a
more effective avenue to tolerance induction. The use of blood transfusions matched for one
HLA-DR antigen with the recipient has produced major benefits in preliminary trials and
represents onestarting point in thisdirection.
Kidney transplantation has evolved to become an effective treatment for patients
with end-stage renal disease. Intertwined with the history of this field over the past
threedecades has been theeffect ofpriorallogeneic blood exposure upon graft survival.
For many years it was customary to remove both diseased kidneys from the potential
recipient to make it easier to manage hypertension, and to lessen the likelihood of
recurrence of the original glomerulonephritic disease. Patients awaiting transplanta-
tion, sustained by dialysis machines, became profoundly anemic, with hematocrits
closeto 15 percent. Manyrequired large numbers ofblood transfusions over a period of
months, as many as 50-100 units in extreme cases, but frequently exceeding 20 units.
With the advent of more effective approaches to blood pressure control, and with the
realization that removal of diseased kidneys plays no role in prevention of recurrent
disease, native kidneys are generally left in place, except in instances of deep-seated
infection in the organs. Even so, many patients benefit symptomatically from blood
transfusions in the range of two to five units per year, with the variation probably
dependent upon the residual production ofEPO by the remnant renal tissue.
CHANGING PRACTICES IN THE PRE-TRANSPLANT USE OF BLOOD
TRANSFUSIONS: AN OVERVIEW
The practiceofblood transfusion over three decades has twice swung back and forth
from one extreme to the other. The first phase was the high-volume use of blood as
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described above in attempts to keep a patient's red cell mass in the 20-25 percent
range. With the realization that blood exposure could be highly immunogenic in many
patients, leading to production of anti-HLA antibodies, which at time of cross-match
precluded transplantation [1], efforts were made in the 1970s in the secondphase to
avoid blood exposure, a policy that was reinforced by growing concerns about the
serious long-term consequences of transfusion-induced hepatitis in the immunosup-
pressed graft recipient [2]. Indeed, the incidence ofhepatitis in the dialysis population
itself was a major concern, and the long-term consequences of hepatic failure were
accelerated in the immunosuppressed graft recipient. Within a few years, reports
appeared suggesting that non-transfused patients receiving cadaveric donor grafts
were, in fact, at highest risk for graft rejection, having a 20-30 percent lower one-year
graft survival rate [3,4]. The subsequent registry tabulation of thousands of cases
showed that, in the pre-cyclosporine era, the failure to transfuse a potential kidney
recipient was the single most powerful factor in prediction of a poor outcome.
Naturally, this finding led to many attempts to define the dose and timing optima for
the transfusion effect. In the first thorough analysis by Opelz et al. there was a distinct
dose effect, with a gradation of one-year survival rates according to the numbers of
blood units received prior to transplantation [4]. There was some improvement from a
single transfusion, with increasing survival rates up to an optimum of 10-20 blood
units. It was, furthermore, shown that the type of blood (fresh, frozen, washed packed
red blood cells) made no difference, and it was the leucocyte component which
mattered. Administration of blood in the perioperative period alone was without effect
[5]. In one study, there was indication that the agglomeration method for blood
preservation resulted in a product which was much less immunogenic in terms of
producing antibodies, while retaining its ability to improve graft results [6]. The
question of how long the favorable effect lasts (e.g., what if one had five transfusions
many years ago, but none since the onset of end-stage renal disease), was difficult to
answer, since few cases had such a history. It seemed clear, however, that blood
received within a year or two had a beneficial effect. As a result of these data, most
centers inphase three followed a deliberate transfusion policyofadministering at least
two to five units while awaiting transplantation. One problem at the time of these
surveys, and continuing today, is the reliability of medical records and ofthe patient's
memory in regard to blood transfusion, especially prior to the initiation of regular
dialysis treatments.
As we entered the 1980s, and cyclosporine was introduced, graft and patient survival
improved, and the question ofthe beneficial role ofblood transfusions and also ofHLA
matching has been subject to ongoing re-evaluation. In large registry data, there has
been an overall decline in the transfusion effect and an increase in the HLA matching
effect. The latter is more clearly recognized now because ofimproved typing capabili-
ties; indeed, the HLA effect is additive to that ofcyclosporine, which itselfproduces a
15 percent increase in one year survival rates [7]. It is also clear, however, that there
had been a progressive improvement, year by year, in graft results, even before the
introduction ofcyclosporine [8]. In centers that report 90 percent one-year cadaveric
graft survivals, it is not possible to discern either an HLA or a transfusion effect,
probably as a result of heavy immunosuppression in the early post-transplant period.
The change in the transfusion effect during the early 1980s, which started before the
introduction ofcyclosporine, is most marked by adisappearance ofthegraded response
to increasing numbers of blood units. Only the deleterious effect of receiving no
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transfusions remains, with a 10 percent lower one-year survival rate, and this result has
been seen whether cyclosporine or traditional azathioprine was used for immunosup-
pression [9]. Subsequent data bases show an almost trivial detriment to the non-
transfused patient group, indicating thatthetransfusion effecthasvirtuallydisappeared
in the transplanted population as a whole [10]. There is no simple explanation for this
trend, yet because of these data we are now entering thefourth phase of transfusion
policy, a return to the withholding of blood as possibly unnecessary, at least for the
improvement of graft survival. With the recent concerns regarding transmission of
viral diseases, including HIV, and with the coming on line ofEPO therapy to maintain
an adequate red cell mass, it is plain that there are clear incentives to move away from
use of pre-transplantation blood transfusions. There are, however, intriguing indica-
tions that blood transfusions may play a very important role in particular patients. The
remainder of this paper will discuss recent evidence that the blood transfusion effect
remains in certain circumstances, when one considers effects of HLA antigens,
rejection episodes, and possibly the prospects oftolerance induction. Unless otherwise
mentioned, the data come from kidney transplantation, as extensive studies with other
organs are unavailable.
THE SPECTRUM OF SENSITIZATION TO HLA AND
EFFECTS OF MATCHING
The preceding overview reflects the behavior ofthe end-stage renal disease popula-
tion as a whole. With closer analysis of the effects of blood transfusions, one realizes
that there are crucial individual differences in the effects ofallogeneic blood exposure.
First, most patients do not develop anti-HLA antibodies, as measured by the usual
cross-match technique of complement-mediated cytotoxicity, following transfusion.
Overall, 30 percent of transfused individuals do develop antibodies, with a higher rate
in previously pregnant females and a lower one in males [11]. In normal multiparous
females, not transfused, about 10 percent make such antibodies, and this response is
usually transient for a few weeks after term. These individuals provide the major
source of anti-HLA typing sera. As noted, multiparous women challenged with blood
transfusions will show an increase in the responder rate to 30-40 percent [11]. Among
all responders, male or female, some have a highly selective immune response directed
to one to four HLA antigens, whileothersshow sensitivity tobetter than 95 percentofa
reference panel. Clearly, there is genetic control over responsiveness, but this control
has not been associated with the putative immune response genes of HLA class II. In
other words, one cannot predict responder status from an individual's HLA phenotype.
Responders and non-responders to blood transfusions declare themselves fairly early
after the initiation of a series of blood transfusions, with very few non-responders
converting after thefirst six months ondialysis. Indeed, there were many patients in the
early era offrequent transfusion whoremained negative onantibody screens after 50or
moretransfusions. Inspection ofwaiting listsforcadaverickidneytransplantation gives
the impression that the responder rate ofhighly sensitized patients is very much higher
than an overall 30 percent. On a typical list, over 50 percent of patients will have
antibodies to more than half of the reference panel, and 20 percent or so will have
antibodies to 90-100 percent. The degree of sensitization is commonly expressed as
"PRA," panel-reactive antibody. Patients with antibodies accumulate over time
because they frequently have positive cross-matches with potential donors. In addition,
many are awaiting second transplants, and this group has a much higher likelihood of
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having anti-HLA antibodies induced by rejection ofthe first graft. Since patients with
antibodies to a given donor are ruled out for that transplant, it is possible that a major
effect ofblood transfusions is to reveal thestrong immune responsepreferences, atleast
in terms ofantibody formation, ofresponder patients. Blood transfusions, in this view,
provide a processofnegative selection, with theresult thattransplantsdestined toearly
failure are avoided. This mechanism most certainly played a role in the pre-
cyclosporine era, especially when there still existed an increasing benefit with higher
numbers of transfusions. These blood exposures were in essence providing surrogates
for first transplants. The contributions ofcyclosporineand other more potenttherapies,
such as anti-lymphocyte globulins (ALG), to the decline in the transfusion effect may
be to suppress those responses previously subject to negative selection by transfusion.
As mentioned, however, the transfusion effect was already declining before the
introduction ofcyclosporine, and it is likely that other factors, such as prompt attention
to the diagnosis and treatment ofearly rejections, may play a role. HLA matching can
also play a role. A recent analysis indicates a benefit from transfusions in HLA-DR
mismatched cases, but not when there were no mismatches. The latter situation alone
produced the same 80 percent one-year survival in both transfused and non-transfused
recipients, while transfusions add an 8-10 percent benefit in the one- and two-DR
mismatched groups [12].
TRANSFUSIONS AND REJECTIONS
Although it may now be difficult to see a transfusion effect in the entire group of
renal transplant recipients, close attention to rejection events provides evidence that
transfusions do have effect in those destined to have rejection activity. In a single-
center study of the controlled reinstitution of a no-transfusion policy, there was no
difference in graft survival comparing transfused and non-transfused patients; how-
ever, the non-transfused group had more early rejection episodes [13]. A nine-center
study on the relation of rejection activity to previous blood transfusions in 567 first
cadaver kidney grafts showed that 63 percent ofthe 231 non-transfused recipients had
rejection episodes during the first 60 days after transplantation, while 48 percent ofthe
transfused patients had rejection [14]. Most striking, however, was the comparison of
one-year graft survivals in those who had rejection and those who did not, in relation to
blood transfusion history. Those with no rejections all had high rates ofsurvival (84-88
percent at one year), whether they had received 0, 1-10, or >10 transfusions. If a
rejection episode occurred, the results were 49 percent one-year survival for no
transfusions, and 70 percent for the transfused patients (Table 1). Hence, the original
deficit of 20 percent poorer survival in the absence of prior transfusions may still be
discerned in those patients destined to reject. Unfortunately, there are no reliable
predictive tests so that one can know who would need to have transfusions prior to
transplantation.
TRANSFUSIONS AND NONSPECIFIC SUPPRESSION OF
CELL-MEDIATED IMMUNITY
There is evidence to support the notion that there is an active mechanism to
down-regulate cellular immunity following transfusion. Serial measurements of cell-
mediated responses in previously non-transfused end-stage renal disease patients have
shown marked reductions in response to mitogens and recall antigens (PPD, tetanus,
mumps, vaccinia) after a single blood transfusion, and lasting for over two weeks [15].
438TRANSFUSIONS AND TRANSPLANTATION
TABLE 1





(First 60 Days) 0 1-10 >25
Yes 49%(n = 145) 69%(n = 135) 71%(n = 25)
No 84% (n = 86) 88% (n = 146) 87% (n = 30)
A second transfusion at four weeks produced a more profound and lasting depression.
There were, however, no significant depressions in the allogeneic HLA-directed mixed
lymphocyte response (MLR). Similar results have been repeated in other populations,
and there are indications that blood transfusions in patientswith cancer may hasten the
recurrence ofmalignancy [16], as well as increasing the risk for infections [17].
ANTIGEN-SPECIFIC UNRESPONSIVENESS
The ultimate goal in transplantation is the induction ofspecific unresponsiveness, or
tolerance, so that patients need not take anti-rejection medications indefinitely, and,
moreimportant, that both the initial and long-term graft survival rates are limited only
by other life-threatening diseases. In this regard, there is considerable interest in
understanding thealtered stateofimmunity in long-term stablepatients maintained on
minimal drug doses. In general, the proliferative response of T cells in vitro to HLA
class II incompatible stimulator cells (MLR) is not depressed in such patients, but the
capability of such cultures to develop cytotoxic T cells (cell-mediated lympholysis,
CML) generally directed to HLAclass I antigens, is absent in 70 percent ofsuch stable
patients six months after transplantation and beyond [18,19]. This unresponsiveness is
specific for donor antigens; i.e., patients make perfectly normal responses to cells
bearing other HLA antigens. When the precursor frequency of cytotoxic T cells
(CTLp) is estimated by the technique of limiting dilution, such subjects are shown to
have marked reductions in cells capable of killing donor cells [20]. The possibility of
clonal deletion seems unlikely, however, since full activation by polyclonal mitogens
will restore the expected CTLp to the normal level of about 1:2,000 [21]. Therefore,
the full T-cell repertoire is present, but, in the absence of stimuli which bypass
inhibitory immunoregulatory influences, the individual is functionally unresponsive.
To date, there is no evidence that blood transfusions lead quickly and directly to
unresponsiveness in CML, and except for the correlation of low CML and good graft
function, there is no direct evidence that this phenomenon is the principal reason for
graft success. It is of interest, however, to note that blood transfusions which do not
produce an increase in CTLp and CML activity are those which share an HLA
haplotype, or at least one DR antigen with the transfused recipient [22]. This situation
occurs when living donor kidney graft recipients are prepared by single-donor blood
transfusions from the potential kidney donor, so-called donor-specific transfusions
(DST). Such recipients, ifthey do not develop a positive cross-match, are reported to
have superior graft survival, close to that of an HLA identical donor [23]. The
frequency of positive cross-matches in DST recipients was in the 30 percent range, as
one would predict, until concurrent administration ofazathioprine or cyclosporine was
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shown to reduce this hazard to 10 percent or less [24,25]. Other studies in such familial
haplotype identical combinations have also pointed to another possible mechanism for
benefits oftransfusion: the induction ofanti-idiotype antibodies having the potential of
inhibiting the recognition of subsequent specific antigen by either antibodies or T-cell
receptors [26,27].
TOLERANCE INDUCED IN UTERO
There is yet another factor to beconsidered in the response to blood transfusions and
organ grafts, and that is the new evidence that many humans behave as if they were
clonally deleted for those HLA antigens of their mothers which they did not inherit.
The presumed mechanism would be similar to that of in utero or neonatal tolerance
induced experimentally. The observation was first made by the van Rood group in
Leiden in an analysis ofthose end-stage renal disease patients having very high PRA,
but consistently having no antibodies against a small number of HLA antigens [28].
Such a small "hole" in the repertoire of antibody response in half of such sensitized
patients is found to be a failure to respond to non-inherited maternal HLA antigens.
This phenomenon has been extended to cell-mediated immunity in the CML assay, in
preliminary studies from the same group. Although not directly related to effects of
blood transfusions, these findings, if confirmed, need to be taken into account when
interpreting states ofspecificunresponsiveness and may even be applicable to selection
ofdonors for transplant recipients.
TOWARD MORE SELECTIVE IMMUNOSUPPRESSION
What ofthe future? Will it be possible to utilize antigen exposure to blood products
as part of a conditioning regimen for tolerance induction? Most fascinating in this
regard are the studies from Leiden on the selection of single blood donors from the
unrelated population to be matched, not for a whole HLA haplotype, but for one DR
antigen only [29]. It has already been mentioned that such transfusions do not increase
sensitivity as measured by CML [22], and that they may induce production of
anti-idiotypic antibodies which can prevent the response of T cells specific to the
immunizing HLA antigens [26,27]. Furthermore, anti-HLA antibodies were less
frequent as result of one DR matched versus no DR matched transfusions (Table 2).
Retrospective studies ofkidney recipients, and prospective studies ofkidney and heart
recipients have shown a reduced rejection frequency and superior graft survival when
the only blood received prior to transplantation was one to three units from donors
matched for one DR antigen with the recipient [29]. Matching for one DR antigen
between the recipient and graft donor provided minimal benefit compared to having
the one DR match between the recipient and the blood donor. The five-year kidney
survival in patients receiving no or one pre-transplant transfusion is shown in Table 2.
There is a significant improvement in results in the one DR group. Comparable results
werereported in the numbersofrejectionsandgraft losses in 20singlytransfused heart
graft recipients, half of whom received a one DR matched blood transfusion (7/10
without rejection versus 1/10 in the unmatched transfusion group) (p = 0.003) [29].
Anti-HLA antibody production was also diminished in the one DR transfused group.
Although the mechanisms for the benefits of one DR matched blood transfusions
from a single donor are not understood, this approach seems promising. The beneficial
effect, though dependent upon a class II match, includesdown-regulation to HLAclass
I antigens ofthe blood donor, as shown by the reduction in antibodies to HLA, and the
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TABLE 2
Effect ofOne and Two HLA-DR Antigen Mismatched Blood





Matches la 3a (one transfusion)
I DR 6/28b 2/16 81% (n =32)
0 DR 18/30 12/16 57%(n =30) (p=0.02)
45% (n = 45)C (p = 0.001)
ap = 0.02 (one transfusion);p = 0.0007 (threetransfusions)
bNumber makingantibodies/total
CNotransfusion controls
effect carries over totheorgangraft regardless ofthe HLAantigens presentonthenew
tissue. In some fashion, the known role of self HLA molecules to present antigenic
peptides to T cells is likely to be a key part of the beneficial effect. It seems unlikely,
however, that the effect is entirely immunologically specific, as the non-matched
haplotype will have only one ofthe ten major DR antigens possible on the subsequent
graft. On the other hand, DR as defined serologically may not be as important as some
more widely shared "public" epitope. Since the improvement observed with a single
blood donor is of the order of having 25 percent fewer graft losses, some of the effect
could indeed represent chance DR sharing between blooddonorand subsequent kidney
donor, and betheresultofimmunization inthecontextofaselfclass II DRantigen toa
foreign DR peptide; i.e., thephenomenon maybe mediated byprimed T cells restricted
to self DR plus peptides coming from the subsequent graft [30]. In this view, the
hypothetical active immunization effect would be one ofsuppression via some antigen-
specific immunoregulatory pathway.
Alternatively, it is possible that provision of "self' DR on intravenously adminis-
tered cells induces a different sort of systemic response similar to the so-called
autologous mixedlymphocyte response (AMLR) whichoccurs whenautologous Tcells
are cultured in vitro with greater numbers of autologous B cells than are normally
present in blood [31]. The AMLR involves a limited subset of T cells and results in
development of a nonspecific suppressor system capable of inhibiting activation of B
and T cells [32], so that the specificity would be to selfin the priming event, and not to
the second immunization by thegraft, which is modified by nonspecific suppression. In
any event, additional confirmatory studies are needed, along with careful study of
possibly different effects when alloantigens are presented in the context of selfversus
non-selfclass II HLA. So far, itdoes not seem thatthe immediate effect ofa single one
DR matched blood transfusion is one ofinduction ofCML unresponsiveness, and data
are lacking on the development or functional significance of anti-idiotypic responses
following transfusions based upon HLA-DR matched blood transfusions.
One should be reminded that these as yet vaguely appreciated events occur in the
setting of immunosuppressive therapies which are likely to be essential for their
expression. By the same token, in considering the future of deliberate pre-transplant
blood transfusions, it is conceivable that heavy loads of standard immunosuppressive
agents could becounterproductive to the induction ofactive states ofunresponsiveness.
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